# Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

> **NCT05239676** · EARLY_PHASE1 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 50 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells

## Key facts

- **NCT ID:** NCT05239676
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-28
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05239676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05239676, "Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05239676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*